closest glp-1 intestinal paralysis lawsuit in kentucky PFAS Water Contamination Attorney There’s been a lot of

Michael Young, MD leads the clinical team

Your healthcare provider can recommend the best approach for your specific situation and medication

The onset can be in the first 16 weeks of treatment, particularly during the first 28 days [49,51,52]

Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD